R3i CAPITAL

Leesa Soulodre is a seasoned venture capital leader as Managing General Partner at R3i Capital, specializing in deep tech and AI investments. She serves as an adjunct faculty at SMU Cox, and is an advocate for women in tech and sustainable development goals.

In an exclusive interview with MedTech Outlook APAC, she shared invaluable insights on building regulatory pathways, fostering inclusive innovation, and accelerating patient access to transformative medical technologies.

The birth of R3i CAPITAL wasn't orchestrated in boardrooms, it was forged at 3 AM in nursing homes and palliative care, watching a brilliant researcher's Alzheimer's treatment fail not because the science was wrong, but because no one would fund the translation from bench to bedside. That gap between promise and patient reality? It's where I've lived my entire career.

My path reads like a medical chart: alzheimer and dementia and palliative care nurse, Australian soldier, disabled veteran, serial entrepreneur, tech operator and investor. Across three continents, I witnessed the same tragedy 95% of digital health innovations dying at borders. Not because they lacked merit, but because Silicon Valley's "move fast and break things" philosophy shatters when the "things" are human lives.

The Megafund Monopoly We're Dismantling

Here's the data that should keep LPs awake: In Q4 2024, the top 20 VC firms captured 87% of institutional commitments (PitchBook). These same firms passed on Airbnb eleven times, told Melanie Perkins Canva would never scale, and consistently miss breakthrough innovations while pattern-matching against expired playbooks.

When I started fundraising, an LP — I kid you not — asked: "But how will you see deals if you're not on Sand Hill Road?" As if innovation gives a damn about ZIP codes. We're backing geographic arbitrage: that researcher in Singapore solving severe dengue hemorrhage on $100K while Palo Alto burns millions on the fifteenth meal delivery app.

"We don’t just fund technology, we bridge the gap between innovation and humanity, turning bold science into life-saving solutions that megafunds overlook"

The numbers tell our story: Emerging managers generate 2.4x better returns than established funds (Cambridge Associates, 2024), yet receive less than 15% of LP capital. Why? Because institutional investors optimize for CYA over IRR , they'd rather explain mediocre returns from Sequoia than transformative outcomes from an unknown.

Navigating the Regulatory Maze (Without Losing Our Minds)

The operational reality? I'm a translator between "FDA's 510(k) pathway takes 6-12 months" and "we need to pivot by Friday." Last month, I worked with a founder whose respiratory AI could prevent 10,000 annual deaths in India alone. The tech works. Clinical validation: bulletproof. But GDPR plus HIPAA plus India's new Digital Personal Data Protection Act? That's a three-year, $2M compliance maze.

Our solution isn't sexy but it works: pre-negotiated regulatory pathways across six jurisdictions, automated compliance platforms that transform marathons into sprints. We only partner with co-investors who measure success in QALYs (Quality-Adjusted Life Years), not just IRR. Because what's the point of a 10x return if it doesn't translate to lives saved?

AI's Healthcare Revolution: Beyond the Hype

Over the last 6 months, I invested 12 hours a day vibe coding built predictive care platforms for respiratory, cardiac, neuro, and infectious diseases. Traditional route: $4.5M and 18 months. My route: $50, four weeks, and an army of AI agents. This isn't iteration, it's the democratization of innovation.

But here's what actually matters: We're evolving from "AI reads X-rays" (old news) to "AI predicts your heart attack 8 days in advance by analyzing IoT data". The convergence of edge computing, federated learning, and critically explainable AI means we can finally deliver precision medicine without sacrificing privacy.

When our models tell cardiologists not just "this patient is at risk" but "here's why, here's the troponin patterns you missed, here's the correlation with their sleep apnea," skeptics become evangelists. That's the bridge between innovation and adoption.

The Founder's Litmus Test

Can you explain your innovation to both a farmer in rural Rajasthan AND a regulator in Luxembourg? Because in Luxembourg, you land day-one facing four languages, MDR, EU AI Act, and GDPR. If you're not thinking regulatory alpha from inception, you're playing checkers while the market demands chess.

Stop building solutions seeking problems. Last week, a founder pitched me after six months perfecting their algorithm without talking to a single clinician. That's like designing a parachute without consulting skydivers technically impressive, practically useless.

The Bridge We're Building

The emerging manager's superpower isn't competing with mega funds it’s recognizing we're playing entirely different games. While they deploy $100M helping the already-successful scale, we write $100k-Million dollar checks helping the truly innovative survive. In healthcare and deep tech, early conviction creates 100x more value than late-stage capital ever could.

We're constructing bridges: Bangkok's frugal innovation to Boston's research centers, Kigali's leapfrog solutions to Luxembourg´s EU landing platform. Because healthcare isn't a technology problem with human complications it’s a human problem that technology, thoughtfully applied, can help solve.

That's our thesis. That's our invitation to every founder bold enough to challenge the status quo. The next decade belongs to builders who honor both innovation and humanity.

Only together, we rise.